Upper airway stimulation for obstructive sleep apnoea: Patient reported outcomes after 48 months of follow-up

Abstract

Introduction: Upper airway stimulation has been shown to be safe and effective in participants with moderate-to-severe OSA in a large cohort study (STAR Trial) after 12 months of follow-up [1]. This study was aimed to assess patient reported outcomes after 48 months of follow-up. Methods: A total of 126 participants received an implanted upper airway stimulation system (Inspire Medical Systems, Minnesota, USA) in a prospective phase III trial. The patient reported outcomes were collected every 6 months including Epworth Sleepiness Scale (ESS) and the Functional Outcomes of Sleep Questionnaire (FOSQ). Results in mean (SD) and paired t-test in comparison with baseline. Results: A total of 96 and 60 participants completed follow up at 42 and 48 months, respectively. Data collection is on-going with 48 month visit completed by June 2016. ESS reduced significantly from 11.6 (5.0) at baseline to 7.0 (4.7) at 42 months (p Conclusion: Upper airway stimulation via cranial nerve XII maintained a sustained benefit on patient reported outcome measures (ESS and FOSQ) up to 4 years of follow-up. Reference: Upper-airway stimulation for obstructive sleep apnea. Strollo PJ, Soose RJ, Maurer JT, et al for the STAR Trial Group. N Engl J Med 2014; 370:139-49.